Clinical trial
Safety and Efficacy of Seroquel in First Episode Schizophrenia
NCT00254241 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00254241 |
|---|---|
| Title | Safety and Efficacy of Seroquel in First Episode Schizophrenia |
| Official title | Safety and Efficacy of Seroquel in First Episode Schizophrenia |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Seroquel and Risperidone |
| Enrollment | 80 |
| Start date | May 1, 2002 |
| Completion | Jun 1, 2006 |
| First posted | Nov 16, 2005 |
| Last update posted | Jun 11, 2009 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: